Skin Tumors Practice Questions

Q: An HIV positive patient presented with the clinical condition as seen in the color plate. Which of the following is the most probable diagnosis?

Kaposi sarcoma. ***Kaposi sarcoma*** - **Kaposi sarcoma** is an **AIDS-defining illness** caused by **HHV-8 (human herpesvirus-8)** and commonly presents as **violaceous (purple-red) plaques or nodules** in HIV-positive patients. - The **immunocompromised state** in HIV patients significantly increases susceptibility to this **vascular tumor**, making it the most probable diagnosis given the clinical context. *Pyogenic Granuloma* - Typically appears as a **red, pedunculated, bleeding lesion** that develops rapidly following trauma or irritation. - Not specifically associated with **HIV infection** or immunocompromised states, and lacks the characteristic **violaceous color** of Kaposi sarcoma. *Linear Gingival Erythema* - Presents as a **distinct red band along the gingival margin** and is a **periodontal condition**, not a tumor. - While it can occur in HIV patients, it manifests as **gingival inflammation** rather than the **nodular skin lesions** typical of Kaposi sarcoma. *Focal Epithelial Hyperplasia* - Caused by **HPV types 13 and 32**, presenting as **multiple small, painless papules** in the oral cavity. - This **benign condition** lacks the **vascular nature** and **violaceous appearance** characteristic of Kaposi sarcoma in HIV patients.

Q: What is the recommended treatment for Stage 1 cutaneous T-cell lymphoma?

PUVA (Psoralen plus Ultraviolet A). **Explanation:** Cutaneous T-cell lymphoma (CTCL), specifically **Mycosis Fungoides (MF)**, is staged based on the extent of skin involvement and systemic spread. Stage 1 (IA and IB) is characterized by patches and plaques involving <10% or ≥10% of the body surface area, respectively, without nodal or visceral involvement. **Why Option A is correct:** For early-stage CTCL (Stage 1), **Skin-Directed Therapy (SDT)** is the first-line treatment. **PUVA (Psoralen plus Ultraviolet A)** is highly effective as it induces apoptosis of the malignant T-cells in the epidermis and dermis. Other SDTs include topical corticosteroids, topical retinoids (Bexarotene), and Narrowband UVB (for thin patches). **Why other options are incorrect:** * **B. Biological response modifiers:** (e.g., Interferon-alpha) are typically reserved for Stage IIB (tumors) or cases refractory to skin-directed therapies. * **C. Systemic chemotherapy:** This is generally avoided in early stages due to toxicity and lack of curative potential. It is reserved for advanced Stage IV disease with visceral involvement. * **D. Extracorporeal photopheresis:** This is the treatment of choice for **Sézary Syndrome** (leukemic phase of CTCL) or erythrodermic MF (Stage III), rather than localized Stage 1 disease. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic feature:** Pautrier’s microabscesses (clusters of atypical T-cells in the epidermis). * **Hallmark cell:** Lutzner cells (T-helper cells with cerebriform nuclei). * **Staging:** Stage IA ( 10% BSA), Stage IIB (Tumors), Stage III (Erythroderma), Stage IV (Visceral/Nodal). * **Treatment Mantra:** "Start local for early stage, systemic for late stage."

Q: A patient presents with pigmented macules on the palm. Histological examination reveals proliferating melanocytes at the dermoepidermal junction. What is the most likely diagnosis?

Junctional nevus. ### Explanation **Correct Option: B. Junctional nevus** The diagnosis is based on the specific anatomical location of the melanocytic proliferation. A **junctional nevus** is characterized histologically by nests or clusters of melanocytes located strictly at the **dermoepidermal junction (DEJ)**. Clinically, these appear as flat (macular), well-circumscribed, and pigmented lesions. They are the most common type of nevus found on **palms, soles, and genitalia**. **Analysis of Incorrect Options:** * **A. Halo nevus:** This is a melanocytic nevus surrounded by a depigmented "halo" caused by an immune-mediated (T-cell) destruction of melanocytes. Histology would show a dense lymphocytic infiltrate. * **C. Dermal melanocytic nevus:** In this type, the melanocytes have migrated entirely into the **dermis**. Clinically, these are typically raised (papular), dome-shaped, and often lose their pigmentation (skin-colored). * **D. Dysplastic nevus:** These show architectural atypia (bridging of nests, shouldering phenomenon) and cytologic atypia. While they involve the junction, the question describes a simple proliferation without features of dysplasia. **High-Yield NEET-PG Pearls:** 1. **Evolution of Nevi:** Nevi often follow a life cycle: Junctional (flat) → Compound (raised/junctional + dermal) → Intradermal (raised/dermal only). 2. **Compound Nevus:** Shows melanocytic nests at both the DEJ and within the dermis. 3. **Abtropfung Effect:** The process where melanocytes "drop off" from the epidermis into the dermis to form a compound or dermal nevus. 4. **Palmar/Plantar Lesions:** Any pigmented macule on acral skin in an adult that shows irregular borders or variegation should be evaluated to rule out **Acral Lentiginous Melanoma**.

Q: What is the treatment for mycosis fungoides syndrome?

Electron beam therapy. **Explanation:** **Mycosis Fungoides (MF)** is the most common type of Cutaneous T-Cell Lymphoma (CTCL). It is characterized by the malignant proliferation of skin-homing CD4+ T-cells. **Why Electron Beam Therapy is Correct:** Total Skin Electron Beam Therapy (TSEBT) is a highly effective treatment for MF because electrons have a limited depth of penetration. Unlike X-rays, electrons deposit their energy primarily in the epidermis and dermis, sparing deeper internal organs. This makes it ideal for treating widespread cutaneous lesions (patches, plaques, or tumors) while minimizing systemic toxicity. It is often considered the gold standard for extensive skin involvement. **Analysis of Incorrect Options:** * **A. 5-Fluorouracil:** This is an antimetabolite used topically for actinic keratosis or superficial basal cell carcinomas, but it is not a standard treatment for MF. * **B. Doxorubicin:** While liposomal doxorubicin may be used in advanced, systemic, or refractory stages of MF, it is not the primary or characteristic treatment modality compared to skin-directed therapies. * **D. Interferon:** Interferon-alpha is an immunomodulatory systemic therapy used for MF, but it is typically a second-line agent or used in combination with other therapies like PUVA. **High-Yield Clinical Pearls for NEET-PG:** * **Staging:** MF progresses through three classic stages: **Patch → Plaque → Tumor**. * **Histology:** Look for **Pautrier’s microabscesses** (clusters of malignant T-cells in the epidermis) and "buttock cells" (cerebriform nuclei). * **Sézary Syndrome:** The leukemic triad of MF consisting of erythroderma, lymphadenopathy, and circulating atypical T-cells (Sézary cells). * **First-line for early stage:** Topical corticosteroids, PUVA (Photochemotherapy), or Narrowband UVB.

Q: A patient presents with diffuse, nonencapsulated fatty deposits. Which of the following is the most likely associated history?

Alcohol dependency. The clinical presentation of diffuse, nonencapsulated fatty deposits is characteristic of **Madelung’s disease**, also known as **Multiple Symmetric Lipomatosis (MSL)**. ### **Explanation of the Correct Answer** **Madelung’s disease** is a rare metabolic condition characterized by the symmetrical accumulation of unencapsulated adipose tissue, typically around the neck ("horse collar" appearance), shoulders, and upper trunk. * **Association:** There is a very strong clinical association with **chronic alcohol dependency** (seen in 60–90% of cases). * **Pathophysiology:** It is thought to involve a defect in the adrenergic-stimulated lipolysis of brown fat, often exacerbated by alcohol's effect on mitochondrial function and lipid metabolism. ### **Analysis of Incorrect Options** * **B. Hypercalcemia:** Not associated with fatty deposits. It is typically linked to subcutaneous fat necrosis of the newborn or calciphylaxis, but not symmetric lipomatosis. * **C. Renal insufficiency:** While associated with metabolic changes, it does not cause diffuse fatty deposits. It is more commonly linked to pruritus, perforating dermatoses, or nephrogenic systemic fibrosis. * **D. Rheumatoid arthritis:** This is an autoimmune inflammatory condition. While patients may have subcutaneous nodules (Rheumatoid nodules), these are firm, localized, and histologically distinct from the diffuse fatty masses seen in Madelung’s. ### **High-Yield Clinical Pearls for NEET-PG** * **Madelung’s Disease (MSL):** Most common in middle-aged males of Mediterranean descent with a history of alcoholism. * **Clinical Appearance:** "Horse collar" (Launois-Bensaude syndrome) or "Hamster cheeks." * **Complications:** While benign, the deposits can cause compression of the trachea or esophagus, leading to dyspnea or dysphagia. * **Treatment:** Alcohol abstinence (to slow progression), surgical excision, or liposuction (though recurrence is common).

Q: What is true about this condition?

Hamartoma of naevo-melanocytes. ***Hamartoma of naevo-melanocytes*** - **Congenital melanocytic nevus (CMN)** is indeed a **hamartoma** composed of proliferating **naevo-melanocytes** (nevus cells). - These are **benign proliferations** of melanocytic cells that are present at birth and represent a developmental malformation. *Increased risk of squamous cell carcinoma* - **CMN** carries an increased risk of **malignant melanoma**, not squamous cell carcinoma. - The **melanoma risk** is particularly significant in **giant CMN** (>20cm diameter) with lifetime risk up to **5-10%**. *Limited to the dermis* - **CMN** typically extends **beyond the dermis** into the **subcutaneous tissue** and sometimes deeper structures. - The **depth of involvement** often correlates with the **size** of the nevus, with larger lesions showing deeper penetration. *Regresses completely by 7 years* - **CMN does not regress** spontaneously and typically **persists throughout life** without treatment. - Unlike **acquired nevi**, congenital lesions are **permanent** and may actually **darken** or become more prominent with age.

Q: In Alibert-Bazin syndrome, the origin of the lymphoma is from which cell type?

T lymphocyte. **Explanation:** **Alibert-Bazin syndrome** is the classic, most common form of **Mycosis Fungoides (MF)**. MF is the most frequent type of **Cutaneous T-Cell Lymphoma (CTCL)**. 1. **Why the correct answer is right:** The neoplastic cells in Alibert-Bazin syndrome are malignant **CD4+ T lymphocytes** (helper T cells). These cells are "skin-homing" because they express Cutaneous Lymphocyte Antigen (CLA). The disease typically progresses through three clinical stages: Patch, Plaque, and Tumor. The hallmark histological feature is the presence of **Pautrier’s microabscesses**, which are intraepidermal clusters of these malignant T cells. 2. **Why the incorrect options are wrong:** * **B lymphocyte:** While B-cell lymphomas can occur in the skin (e.g., Primary Cutaneous Marginal Zone Lymphoma), Alibert-Bazin syndrome is specifically a T-cell malignancy. * **Eosinophil:** Eosinophils may be seen in the inflammatory infiltrate of various skin diseases, but they are myeloid cells and do not undergo malignant transformation in MF. * **Monocyte:** Monocytes are precursors to macrophages and dendritic cells. While they play a role in the immune environment, they are not the cell of origin for this lymphoma. **High-Yield Clinical Pearls for NEET-PG:** * **Sezary Syndrome:** The leukemic variant of CTCL characterized by the triad of erythroderma, lymphadenopathy, and atypical circulating T cells (**Sezary cells** with "cerebriform" nuclei). * **Histology:** Look for **Pautrier’s microabscesses** and **Lutzner cells** (atypical T cells with indented nuclei). * **Treatment:** Early stages are treated with skin-directed therapies (PUVA, topical steroids, nitrogen mustard); advanced stages may require systemic chemotherapy or Brentuximab vedotin (anti-CD30).

Q: What is the most common site for the lentigo maligna subtype of malignant melanoma?

Face. **Explanation:** **Lentigo Maligna Melanoma (LMM)** is a subtype of malignant melanoma that arises from a pre-existing **Lentigo Maligna** (Hutchinson’s freckle). The primary underlying medical concept is **chronic, cumulative sun exposure**. Unlike other forms of melanoma that may be triggered by intermittent blistering sunburns, LMM occurs on skin that has undergone extensive actinic damage over decades. Therefore, it is most commonly found on the **face** (especially the cheeks and nose) of elderly individuals. **Analysis of Options:** * **Face (Correct):** As the most chronically sun-exposed area of the body, the face is the classic site for Lentigo Maligna. It typically presents as a slow-growing, irregularly pigmented macule. * **Palms and Soles (Incorrect):** These are the characteristic sites for **Acral Lentiginous Melanoma**, which is the most common subtype in dark-skinned individuals (Asians and African Americans) and is not related to sun exposure. * **Trunk (Incorrect):** The trunk is the most common site for **Superficial Spreading Melanoma** (the most common subtype overall) in men, often associated with intermittent sun exposure. * **Buttocks (Incorrect):** This is a sun-protected area; melanoma here is rare and would not be the Lentigo Maligna subtype. **High-Yield Clinical Pearls for NEET-PG:** 1. **Most common subtype overall:** Superficial Spreading Melanoma. 2. **Best prognosis:** Lentigo Maligna Melanoma (due to long radial growth phase). 3. **Worst prognosis:** Nodular Melanoma (due to early vertical growth phase). 4. **ABCDE Criteria:** Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving. 5. **Breslow’s Depth:** The most important prognostic factor (measures vertical thickness in mm).

Q: A 45-year-old man is worried about a dark pigmented skin lesion on his arm. The 'mole' is 3 mm wide, symmetric with a regular border and even pigmentation. He reports no change in size or other symptoms. Which of the following is the most appropriate next step in management?

Observation only. ### Explanation The management of a pigmented skin lesion is guided by the **ABCDE criteria** used to screen for malignant melanoma. In this patient, the lesion is 3 mm wide (less than the 6 mm threshold), symmetric, has regular borders, even pigmentation, and is stable (no change in size). These features are characteristic of a **benign melanocytic nevus** [1]. **Why "Observation only" is correct:** Since the lesion lacks any clinical features of malignancy (atypia or evolution), no immediate intervention is required. Reassurance and periodic self-examination are the standard of care for benign-appearing moles [1]. **Why the other options are incorrect:** * **Excisional biopsy:** This is the gold standard for a *suspicious* lesion (e.g., meeting ABCDE criteria). Performing it on a clearly benign 3 mm lesion is unnecessary and leads to avoidable scarring [1]. * **Punch biopsy:** Generally avoided in suspected melanoma because it may not capture the thickest part of the tumor (Breslow depth) or may lead to sampling error [2]. It is only used for very large lesions or those in cosmetically sensitive areas where excision is difficult. * **Chemotherapy, then surgical excision:** This is never the initial step. Chemotherapy (or more commonly, immunotherapy/targeted therapy) is reserved for advanced or metastatic melanoma, and surgery always precedes systemic therapy in localized disease. ### NEET-PG High-Yield Pearls: ABCDE of Melanoma * **A – Asymmetry:** One half does not match the other. * **B – Border:** Irregular, notched, or blurred edges. * **C – Color:** Variegated (multiple shades of brown, black, blue, or red). * **D – Diameter:** >6 mm (though smaller melanomas exist). * **E – Evolving:** Any change in size, shape, color, or new symptoms like itching/bleeding. * **Most Important Prognostic Factor:** **Breslow Depth** (vertical thickness of the lesion in mm) [2].

Question 1

An HIV positive patient presented with the clinical condition as seen in the color plate. Which of the following is the most probable diagnosis?

Accepted Answer

Kaposi sarcoma

Answer

Pyogenic Granuloma

Answer

Linear Gingival Erythema

Answer

Focal Epithelial Hyperplasia

Question 2

What is the recommended treatment for Stage 1 cutaneous T-cell lymphoma?

Accepted Answer

PUVA (Psoralen plus Ultraviolet A)

Answer

Biological response modifiers

Answer

Systemic chemotherapy

Answer

Extracorporeal photopheresis

Question 3

A patient presents with pigmented macules on the palm. Histological examination reveals proliferating melanocytes at the dermoepidermal junction. What is the most likely diagnosis?

Accepted Answer

Junctional nevus

Answer

Halo nevus

Answer

Dermal melanocytic nevus

Answer

Dysplastic nevus

Question 4

What is the treatment for mycosis fungoides syndrome?

Accepted Answer

Electron beam therapy

Answer

5-Fluorouracil

Answer

Doxorubicin

Answer

Interferon

Question 5

A patient presents with diffuse, nonencapsulated fatty deposits. Which of the following is the most likely associated history?

Accepted Answer

Alcohol dependency

Answer

Hypercalcemia

Answer

Renal insufficiency

Answer

Rheumatoid arthritis

Question 6

What is true about this condition?

Accepted Answer

Hamartoma of naevo-melanocytes

Answer

Increased risk of squamous cell carcinoma

Answer

Limited to the dermis

Answer

Regresses completely by 7 years

Question 7

In Alibert-Bazin syndrome, the origin of the lymphoma is from which cell type?

Accepted Answer

T lymphocyte

Answer

Eosinophil

Answer

B lymphocyte

Answer

Monocyte

Question 8

What is the most common presentation of blue rubber bleb nevus syndrome?

Accepted Answer

Asymptomatic iron deficiency anemia

Answer

Cardiac conduction defects

Answer

Renal aminoaciduria

Answer

Painful peripheral neuropathy

Question 9

What is the most common site for the lentigo maligna subtype of malignant melanoma?

Accepted Answer

Face

Answer

Palms and soles

Answer

Trunk

Answer

Buttocks

Question 10

A 45-year-old man is worried about a dark pigmented skin lesion on his arm. The 'mole' is 3 mm wide, symmetric with a regular border and even pigmentation. He reports no change in size or other symptoms. Which of the following is the most appropriate next step in management?

Accepted Answer

Observation only

Answer

Excisional biopsy

Answer

Punch biopsy

Answer

Chemotherapy, then surgical excision

Skin Tumors — MCQs

Skin Tumors — MCQs

On this page

Practice by Chapter

Want unlimited practice?